ARandomized, Double Blind, Phase 3 Study of Docetaxel and Ramucirumab versusDocetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum Based Therapy

 

Randomized,Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non- Small Cell Lung Cancer

http://www.clinicaltrials.gov/ct2/show/NCT00762034 

A Phase III, Randomized, Double Blind andPlacebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha andRibavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis CInfection. 

Safety and Efficacy of 120mg and 240mg BI201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirinfor Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCVCo-infected Patients. A Multinational, Randomized, Parallel Group, Open-labelTrial.

http://www.clinicaltrials.gov/ct2/show/NCT01399619 

A Phase III, Open-label Study of Once DailyBI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a(PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis CInfection Who Failed a Prior PegIFN / RBV Treatment 

http://www.clinicaltrials.gov/ct2/show/NCT01330316 

A Phase III, Randomized, Double-blind andPlacebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) inPatients With Genotype 1 Chronic Hepatitis C Infection Who Failed a PriorPegIFN/RBV Treatment 

http://www.clinicaltrials.gov/ct2/show/NCT01358864 

Cardiology

 

Long term safety and tolerability of REGN727/SAR236553in high cardiovascular risk patients with hypercholesterolemia not adequatelycontrolled with their lipid modifying therapy: a randomized, double-blind placebo-controlled study.

http://www.clinicaltrials.gov/ct2/show/NCT01507831 

  

Nephrology

A Prospective, Multicenter, Randomized Evaluator-Blinded Comparator-Controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections(cSSSI) and Staphlococcus Aureus Bacteremia among Subjects ofModerate or Severe Renal Impairment